MedPath

FRED HUTCHINSON CANCER CENTER

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website
https://www.fredhutch.org
darkdaily.com
·

University of Missouri-Kansas City Study Finds Colorectal Cancer Cases Up 500% among Children

Colorectal cancer cases have significantly increased among younger age groups, leading to potential changes in screening guidelines and increased demand for clinical laboratory tests.
healthday.com
·

2008-2022 Saw Rise in Industry-Sponsored Adult Cancer Clinical Trials

A study in the Journal of Clinical Oncology found a growing reliance on industry for cancer clinical research in the U.S., with an 8.1 enrollment ratio for industry vs. federal sponsors from 2018 to 2022, up from 4.8 during 2008 to 2012.
openpr.com
·

Cytokine Release Syndrome Treatment Market 2034: Clinical

The Cytokine Release Syndrome market is expected to surge due to increasing disease prevalence and awareness, with multiple-stage pipeline products revolutionizing market dynamics. The market report covers epidemiology, emerging drugs, current treatment practices, and market size from 2020 to 2034 in the United States, EU5, and Japan. Key companies and therapies include Swedish Orphan Biovitrum, Incyte , Kite (Gilead), Jazz Pharmaceuticals , and therapies like KINERET (anakinra) and Itacitinib . Market drivers include increasing incidence and R&D activities, while barriers include lack of awareness and misdiagnosis.
nbcnews.com
·

Why some doctors see a downside to notifying women about dense breasts

Women 40+ receive breast density notifications with mammogram reports due to FDA rule, which standardizes messages. Dense tissue makes cancer harder to detect on mammograms and is a risk factor. Women with dense breasts are encouraged to discuss additional imaging tests with their doctors, though experts disagree on the necessity and risks of extra screening. The FDA aims to empower women with clear information, but some argue notifications oversimplify a complex issue.
ascopost.com
·

Bridging the Gap in Cancer Clinical Trial Funding

Industry-sponsored cancer clinical trials doubled from 2008-2022, while federally supported trials remained flat, raising concerns over research gaps in less profitable areas. Diversified funding and advocacy are needed to sustain progress and ensure all patient populations benefit.
news-medical.net
·

Concerns rise over increased industry sponsorship in cancer clinical trials

Industry-sponsored cancer clinical trials in the U.S. have doubled, while federally supported trials remain flat, raising concerns over critical research gaps in cancer prevention, screening, and health disparities. Diversified funding and advocacy are needed to ensure all patient populations benefit.
globenewswire.com
·

Kineta Announces KVA12123 Abstract Accepted for Poster

Kineta 's abstract on KVA12123 clinical program accepted for poster presentation at SITC 40th Annual Meeting, Nov 6-10, 2024. Jason Henry M.D. to present new clinical data on KVA12123, a VISTA blocking immunotherapy, on Nov 8, 2024.
fredhutch.org
·

Bottleneck breakthrough

Researchers at Fred Hutch Cancer Center identify SLC35A2 protein favoring R5 HIV-1 variants over X4, potentially aiding vaccine development.
fredhutch.org
·

Making the most of a small supply

Patient advocates successfully lobbied Congress to increase DOD funding for rare cancer research, leading to a $7.5 million grant for a rare cancers program. This funding supports multi-omics characterization, preclinical model development, and web-based resources for rare liver tumors, fostering collaboration among researchers to accelerate rare cancer research.
cgtlive.com
·

News in Cell and Gene Therapy for Rare Cancer Day 2024

Vironexis Biotherapeutics ' VNX-101 , an AAV vector-based gene therapy, received FDA clearance for a phase 1/2 trial in CD19+ acute lymphoblastic leukemia. CARsgen completed patient enrollment in a pivotal phase 2 trial for satricabtagene autoleucel in China for advanced gastric/gastroesophageal cancer. Adaptimmune's TCR T-cell therapy afami-cel received FDA approval for synovial sarcoma. Mustang Bio 's MB-106 CAR-T therapy achieved a 90% response rate in Waldenstrom macroglobulinemia patients. Wugen 's WU-CART-007 showed improved overall response rates with an enhanced lymphodepletion regimen in T-cell malignancy patients.
© Copyright 2025. All Rights Reserved by MedPath